Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

A summary of the included study characteristics. by Zahra Tajik (20752452)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>" by Kira Shaw (18796168)

Patient demographics. by Yongwoo Lee (2265172)

“…When the vertical distribution was analyzed by further subdivision into six equal parts from top to bottom, the average difference in LLT decreased in the uppermost segment after treatment.…”

a-d. Difference in (a) probing depth; (b) clinical attachment level; (c) bleeding on probing, and (d) plaque index values between baseline and six months after treatment using syst... by Iva Milinkovic (22331710)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Difference in (a) IL-17, and (b) TNF-α relative gene expression levels between baseline and six months after treatment using systemic and local antibiotic treatment. by Iva Milinkovic (22331710)

Subjects:

A flow diagram of the study entry. by Sakiko Fukui (387048)

“…We created a time-series dataset for 69 participants, documenting their average weekly food intake (on a scale of 0-10). …”

Supplementary Material for: Decreased Quality of Life in patients who desire Body Contouring Surgery after Bariatric Metabolic Surgery: A multicenter longitudinal analysis by Dijkhorst P.J. (20584910)

Participants enrollment. by Chikondi Maluwa (20660522)

Subjects:

KAP assessment scores (n = 422). by Chikondi Maluwa (20660522)

Subjects:

Percentage of positive responses to overall satisfaction 2011/12 by A) Age and sex B) SIMD decile C) Number of Health Issues and D) Urban/Rural Class. by David Henderson (4612354)

Subjects:

Percentage of positive responses to access question 2011/12 by A) Age and sex B) SIMD decile C) Number of Health Issues and D) Urban/Rural Class. by David Henderson (4612354)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects: